[Announcement text for desktop] [Shorter announcement text for mobile] Learn more

On October 28, I stood at a podium on the FDA's White Oak campus to share my perspective on the agency's new Rare Disease Framework Initiative. I was one of more than 70 people providing public comment that day, with over 200 attending in person and nearly 3,000 joining online.
I've been advocating in the neuromuscular community for a long time. As the mother of an adult son living with Duchenne muscular dystrophy, I've attended many different kinds of FDA meetings over the years. But this one felt different.
The FDA launched the initiative on October 14 with a white paper titled A New Framework for Rare Disease Review. The need for a dedicated approach is clear: 95% of rare diseases still have no approved treatment, and the clinical development challenges associated with rare diseases often differ significantly from those of more common conditions.
Small patient populations, limited natural history data, geographically dispersed patients, and difficulty recruiting enough participants can make traditional approaches to drug development and regulatory review particularly challenging.
The FDA’s new initiative aims to establish a more consistent, predictable approach tailored to these realities from the outset.
For years, rare disease families have heard about "regulatory flexibility." Because traditional clinical trials aren't always feasible for small patient populations, the FDA has allowed different approaches to generating the evidence needed to evaluate potential treatments.
That flexibility has helped. But it hasn't always provided the predictability or consistency that patients, researchers, and drug developers need.
The new framework aims to establish clearer expectations tailored to rare diseases from the beginning. The FDA calls this a "fit-for-purpose" approach, one that considers the characteristics of each disease, the needs of its patients, and the evidence that can realistically be generated from small populations.
The FDA has outlined several priorities, including:
The goal isn't to lower scientific standards. It's to establish an approach that recognizes the realities of rare disease research rather than treating them as exceptions.
One message came through clearly during the public meeting: Patient input should become an expectation for sponsors, not a nice-to-have.
Since October, rare disease advocates and advocacy groups have been working to make the most of this opportunity. Much of the framework discussion has focused on endpoints, natural history data, and manufacturing considerations. Those topics matter.
But a fit-for-purpose framework should also account for the practical realities of participation.
Rare disease patients are often geographically dispersed. Travel, demanding procedures, and time away from work and family can make participation difficult, particularly for people living with progressive conditions.
At the meeting, Raphael Hebert of I AM ALS spoke to the importance of involving patients in decisions that directly affect their ability to participate:
“We know which losses matter, what risk we may accept, and which trial requirements make participation impossible.”
A trial can be scientifically sound on paper and still be unrealistic for the people it needs to enroll.
That's why patient input needs to come early enough to influence trial design. Patients and caregivers can help identify which procedures, visit schedules, and travel demands are realistic, and what it would take to make participation possible for more members of their communities.
Bringing study visits, assessments, and data collection closer to where patients live, including into their homes, can expand opportunities to participate, ease caregiver burden, and help participants remain in studies. Patient-reported outcomes and data collected through digital health technologies at home may also contribute valuable evidence in small trials.
A framework designed around the realities of rare diseases should also reflect the realities of the people living with them.
The FDA has said this is the beginning of the work, not a finished framework. Roundtables and further discussions come next, and the agency is asking the rare disease community to think big and offer specific solutions.
Written public comments are open through December 11, 2026, under docket FDA-2026-N-12214.
If you're a patient, caregiver, advocate, researcher, or sponsor, I encourage you to submit your comments to the FDA. Tell the FDA what would make research possible for your community.
The rare disease community has waited a long time for a framework built around its realities. This is our chance to help shape it.
